Correlation Between Karyopharm Therapeutics and Protagonist Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and Protagonist Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and Protagonist Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Karyopharm Therapeutics and Protagonist Therapeutics, you can compare the effects of market volatilities on Karyopharm Therapeutics and Protagonist Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of Protagonist Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and Protagonist Therapeutics.

Diversification Opportunities for Karyopharm Therapeutics and Protagonist Therapeutics

0.61
  Correlation Coefficient

Poor diversification

The 3 months correlation between Karyopharm and Protagonist is 0.61. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and Protagonist Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Protagonist Therapeutics and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with Protagonist Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Protagonist Therapeutics has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and Protagonist Therapeutics go up and down completely randomly.

Pair Corralation between Karyopharm Therapeutics and Protagonist Therapeutics

Given the investment horizon of 90 days Karyopharm Therapeutics is expected to generate 1.77 times more return on investment than Protagonist Therapeutics. However, Karyopharm Therapeutics is 1.77 times more volatile than Protagonist Therapeutics. It trades about -0.03 of its potential returns per unit of risk. Protagonist Therapeutics is currently generating about -0.06 per unit of risk. If you would invest  71.00  in Karyopharm Therapeutics on September 26, 2024 and sell it today you would lose (11.00) from holding Karyopharm Therapeutics or give up 15.49% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Karyopharm Therapeutics  vs.  Protagonist Therapeutics

 Performance 
       Timeline  
Karyopharm Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Karyopharm Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders.
Protagonist Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Protagonist Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's technical and fundamental indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Karyopharm Therapeutics and Protagonist Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Karyopharm Therapeutics and Protagonist Therapeutics

The main advantage of trading using opposite Karyopharm Therapeutics and Protagonist Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, Protagonist Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protagonist Therapeutics will offset losses from the drop in Protagonist Therapeutics' long position.
The idea behind Karyopharm Therapeutics and Protagonist Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Other Complementary Tools

Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope